Why Spectrum Pharma Is Poised to Bounce Back

Why Spectrum Pharma Is Poised to Bounce Back

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Spectrum Pharmaceuticals has earned a respected four-star ranking.

With that in mind, let's take a closer look at Spectrum and see what CAPS investors are saying about the stock right now.


Headquarters (founded)

Henderson, Nev. (1987)

Market Cap

$475.9 million



Trailing-12-Month Revenue

$211 million


Chairman/CEO Dr. Rajesh Shrotriya
CFO Kurt Gustafson

Return on Equity (average, past 3 years)



$124.4 million / $50.0 million


Teva Pharmaceutical

Sources: S&P Capital IQ and Motley Fool CAPS.

Earlier today, CAPS All-Star zzlangerhans succinctly summed up the Spectrum bull case for our community:

Since the big plunge in March, the stock has traded between 7 and 9 as the street apparently awaits a revenue trend. The latest quarterly numbers weren't much of a help, as Zevalin declined while Fusilev and Folotyn ticked up. I'm unenthusiastic about the Marqibo acquisition and the company was very vague about the prospects for apaziquone in the last CC. Probably the brightest light on the horizon is belinostat, although it seems that the prior goal of a late summer NDA submission won't be happening. In short, I'm not expecting great things from this outperform but I see it as a low risk move as the share price dips to the lower end of recent range.

But while you can certainly make big gains in tempting turnaround opportunities, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Why Spectrum Pharma Is Poised to Bounce Back originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.